Viridian Therapeutics Statistics
Share Statistics
Viridian Therapeutics has 81.59M
shares outstanding. The number of shares has increased by 27.67%
in one year.
| Shares Outstanding | 81.59M |
| Shares Change (YoY) | 27.67% |
| Shares Change (QoQ) | 2.87% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,324 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 10.55M, so 12.93% of the outstanding
shares have been sold short.
| Short Interest | 10.55M |
| Short % of Shares Out | 12.93% |
| Short % of Float | 13.5% |
| Short Ratio (days to cover) | 12.77 |
Valuation Ratios
The PE ratio is -4.82 and the forward
PE ratio is -3.68.
Viridian Therapeutics's PEG ratio is
0.19.
| PE Ratio | -4.82 |
| Forward PE | -3.68 |
| PS Ratio | 4309.18 |
| Forward PS | 1.2 |
| PB Ratio | 1.94 |
| P/FCF Ratio | -5.59 |
| PEG Ratio | 0.19 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Viridian Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.43,
with a Debt / Equity ratio of 0.03.
| Current Ratio | 15.43 |
| Quick Ratio | 15.43 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.08 |
| Debt / FCF | -0.09 |
| Interest Coverage | -98.17 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $2,111.89 |
| Profits Per Employee | $-1,887,755.24 |
| Employee Count | 143 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 24.74% in the
last 52 weeks. The beta is 0.46, so Viridian Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.46 |
| 52-Week Price Change | 24.74% |
| 50-Day Moving Average | 13.2 |
| 200-Day Moving Average | 17.82 |
| Relative Strength Index (RSI) | 60.81 |
| Average Volume (20 Days) | 889,455 |
Income Statement
In the last 12 months, Viridian Therapeutics had revenue of 302K
and earned -269.95M
in profits. Earnings per share was -3.98.
| Revenue | 302K |
| Gross Profit | -938K |
| Operating Income | -299.04M |
| Net Income | -269.95M |
| EBITDA | -265.66M |
| EBIT | -266.9M |
| Earnings Per Share (EPS) | -3.98 |
Full Income StatementBalance Sheet
The company has 99.59M in cash and 21.09M in
debt, giving a net cash position of 78.5M.
| Cash & Cash Equivalents | 99.59M |
| Total Debt | 21.09M |
| Net Cash | 78.5M |
| Retained Earnings | -995.86M |
| Total Assets | 660.98M |
| Working Capital | 623.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -232.32M
and capital expenditures -511K, giving a free cash flow of -232.83M.
| Operating Cash Flow | -232.32M |
| Capital Expenditures | -511K |
| Free Cash Flow | -232.83M |
| FCF Per Share | -3.43 |
Full Cash Flow StatementMargins
Gross margin is -310.6%, with operating and profit margins of -99018.21% and -89387.09%.
| Gross Margin | -310.6% |
| Operating Margin | -99018.21% |
| Pretax Margin | -89387.09% |
| Profit Margin | -89387.09% |
| EBITDA Margin | -87967.88% |
| EBIT Margin | -99018.21% |
| FCF Margin | -77096.03% |
